1887

Abstract

Simian–human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodeficiency virus type 1 (HIV-1) isolate MNA, designated SHIV MNA, was generated through intracellular homologous recombination. SHIV MNA inherited biological properties from the parental HIV-1, including CCR5 co-receptor preference, resistance to neutralization by the anti-V3 loop mAb KD-247 and loss of resistance in the presence of the CD4-mimic small-molecule YYA-021. SHIV MNA showed productive replication in rhesus macaque PBMCs. Experimental infection of a rhesus macaque with SHIV MNA caused a transient but high titre of plasma viral RNA and a moderate antibody response. Immunoglobulin in the plasma at 24 weeks post-infection was capable of neutralizing SHIV MNA in the presence but not in the absence of YYA-021. SHIV MNA could serve a model for development of novel therapeutic interventions based on CD4-mimic-mediated conversion of envelope protein susceptible to antibody neutralization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.055590-0
2013-12-01
2019-10-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/12/2710.html?itemId=/content/journal/jgv/10.1099/vir.0.055590-0&mimeType=html&fmt=ahah

References

  1. Davis K. L., Bibollet-Ruche F., Li H., Decker J. M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J. A.. & other authors ( 2009a;). Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. . J Virol 83:, 1240–1259. [CrossRef][PubMed]
    [Google Scholar]
  2. Davis K. L., Gray E. S., Moore P. L., Decker J. M., Salomon A., Montefiori D. C., Graham B. S., Keefer M. C., Pinter A.. & other authors ( 2009b;). High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. . Virology 387:, 414–426. [CrossRef][PubMed]
    [Google Scholar]
  3. Decker J. M., Bibollet-Ruche F., Wei X., Wang S., Levy D. N., Wang W., Delaporte E., Peeters M., Derdeyn C. A.. & other authors ( 2005;). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. . J Exp Med 201:, 1407–1419. [CrossRef][PubMed]
    [Google Scholar]
  4. Eda Y., Takizawa M., Murakami T., Maeda H., Kimachi K., Yonemura H., Koyanagi S., Shiosaki K., Higuchi H.. & other authors ( 2006;). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. . J Virol 80:, 5552–5562. [CrossRef][PubMed]
    [Google Scholar]
  5. Fujita Y., Otsuki H., Watanabe Y., Yasui M., Kobayashi T., Miura T., Igarashi T.. ( 2013;). Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination. . Virology 436:, 100–111. [CrossRef][PubMed]
    [Google Scholar]
  6. Gray E. S., Moore P. L., Choge I. A., Decker J. M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K.. & other authors ( 2007;). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. . J Virol 81:, 6187–6196. [CrossRef][PubMed]
    [Google Scholar]
  7. Igarashi T., Endo Y., Englund G., Sadjadpour R., Matano T., Buckler C., Buckler-White A., Plishka R., Theodore T.. & other authors ( 1999;). Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. . Proc Natl Acad Sci U S A 96:, 14049–14054. [CrossRef][PubMed]
    [Google Scholar]
  8. Kong L., Sattentau Q. J.. ( 2012;). Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. . J AIDS Clin Res S8:, 3.[PubMed]
    [Google Scholar]
  9. Kwong P. D., Mascola J. R.. ( 2012;). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. . Immunity 37:, 412–425. [CrossRef][PubMed]
    [Google Scholar]
  10. Landau N. R., Page K. A., Littman D. R.. ( 1991;). Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. . J Virol 65:, 162–169.[PubMed]
    [Google Scholar]
  11. Li M., Gao F., Mascola J. R., Stamatatos L., Polonis V. R., Koutsoukos M., Voss G., Goepfert P., Gilbert P.. & other authors ( 2005;). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. . J Virol 79:, 10108–10125. [CrossRef][PubMed]
    [Google Scholar]
  12. Lusso P., Earl P. L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., Longhi R., Berger E. A., Burastero S. E.. ( 2005;). Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. . J Virol 79:, 6957–6968. [CrossRef][PubMed]
    [Google Scholar]
  13. Madani N., Schön A., Princiotto A. M., Lalonde J. M., Courter J. R., Soeta T., Ng D., Wang L., Brower E. T.. & other authors ( 2008;). Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. . Structure 16:, 1689–1701. [CrossRef][PubMed]
    [Google Scholar]
  14. Mascola J. R., Stiegler G., VanCott T. C., Katinger H., Carpenter C. B., Hanson C. E., Beary H., Hayes D., Frankel S. S.. & other authors ( 2000;). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. . Nat Med 6:, 207–210. [CrossRef][PubMed]
    [Google Scholar]
  15. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho D. D.. ( 1995;). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. . J Virol 69:, 101–109.[PubMed]
    [Google Scholar]
  16. Narumi T., Ochiai C., Yoshimura K., Harada S., Tanaka T., Nomura W., Arai H., Ozaki T., Ohashi N.. & other authors ( 2010;). CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. . Bioorg Med Chem Lett 20:, 5853–5858. [CrossRef][PubMed]
    [Google Scholar]
  17. Narumi T., Arai H., Yoshimura K., Harada S., Nomura W., Matsushita S., Tamamura H.. ( 2011;). Small molecular CD4 mimics as HIV entry inhibitors. . Bioorg Med Chem 19:, 6735–6742. [CrossRef][PubMed]
    [Google Scholar]
  18. Narumi T., Arai H., Yoshimura K., Harada S., Hirota Y., Ohashi N., Hashimoto C., Nomura W., Matsushita S., Tamamura H.. ( 2013;). CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. . Bioorg Med Chem 21:, 2518–2526. [CrossRef][PubMed]
    [Google Scholar]
  19. Nishimura Y., Igarashi T., Haigwood N. L., Sadjadpour R., Donau O. K., Buckler C., Plishka R. J., Buckler-White A., Martin M. A.. ( 2003;). Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. . Proc Natl Acad Sci U S A 100:, 15131–15136. [CrossRef][PubMed]
    [Google Scholar]
  20. Nishimura Y., Shingai M., Willey R., Sadjadpour R., Lee W. R., Brown C. R., Brenchley J. M., Buckler-White A., Petros R.. & other authors ( 2010;). Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. . J Virol 84:, 4769–4781. [CrossRef][PubMed]
    [Google Scholar]
  21. Platt E. J., Wehrly K., Kuhmann S. E., Chesebro B., Kabat D.. ( 1998;). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. . J Virol 72:, 2855–2864.[PubMed]
    [Google Scholar]
  22. Shibata R., Adachi A.. ( 1992;). SIV/HIV recombinants and their use in studying biological properties. . AIDS Res Hum Retroviruses 8:, 403–409. [CrossRef][PubMed]
    [Google Scholar]
  23. Shimizu Y., Okoba M., Yamazaki N., Goto Y., Miura T., Hayami M., Hoshino H., Haga T.. ( 2006;). Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. . Microbes Infect 8:, 105–113. [CrossRef][PubMed]
    [Google Scholar]
  24. Shinohara K., Sakai K., Ando S., Ami Y., Yoshino N., Takahashi E., Someya K., Suzaki Y., Nakasone T.. & other authors ( 1999;). A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. . J Gen Virol 80:, 1231–1240.[PubMed]
    [Google Scholar]
  25. Thali M., Moore J. P., Furman C., Charles M., Ho D. D., Robinson J., Sodroski J.. ( 1993;). Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. . J Virol 67:, 3978–3988.[PubMed]
    [Google Scholar]
  26. von Brunn A., Brand M., Reichhuber C., Morys-Wortmann C., Deinhardt F., Schödel F.. ( 1993;). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. . Vaccine 11:, 817–824. [CrossRef][PubMed]
    [Google Scholar]
  27. Wei X., Decker J. M., Liu H., Zhang Z., Arani R. B., Kilby J. M., Saag M. S., Wu X., Shaw G. M., Kappes J. C.. ( 2002;). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. . Antimicrob Agents Chemother 46:, 1896–1905. [CrossRef][PubMed]
    [Google Scholar]
  28. Wyatt R., Kwong P. D., Desjardins E., Sweet R. W., Robinson J., Hendrickson W. A., Sodroski J. G.. ( 1998;). The antigenic structure of the HIV gp120 envelope glycoprotein. . Nature 393:, 705–711. [CrossRef][PubMed]
    [Google Scholar]
  29. Yamada Y., Ochiai C., Yoshimura K., Tanaka T., Ohashi N., Narumi T., Nomura W., Harada S., Matsushita S., Tamamura H.. ( 2010;). CD4 mimics targeting the mechanism of HIV entry. . Bioorg Med Chem Lett 20:, 354–358. [CrossRef][PubMed]
    [Google Scholar]
  30. Yoshimura K., Harada S., Shibata J., Hatada M., Yamada Y., Ochiai C., Tamamura H., Matsushita S.. ( 2010;). Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. . J Virol 84:, 7558–7568. [CrossRef][PubMed]
    [Google Scholar]
  31. Yusa K., Maeda Y., Fujioka A., Monde K., Harada S.. ( 2005;). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. . J Biol Chem 280:, 30083–30090. [CrossRef][PubMed]
    [Google Scholar]
  32. Zhao Q., Ma L., Jiang S., Lu H., Liu S., He Y., Strick N., Neamati N., Debnath A. K.. ( 2005;). Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. . Virology 339:, 213–225. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.055590-0
Loading
/content/journal/jgv/10.1099/vir.0.055590-0
Loading

Data & Media loading...

Supplementary material 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error